Kazakhstan became the first country in the Eurasian region and Central Asia where Pfizer plans to establish contract production of the innovative vaccine
Kazakhstan’s SK-Pharmacy and Pfizer international bio-pharmaceutical company entered into a long-term agreement, as per which the pharmaceutical giant undertakes to supply a 20-valent pneumococcal conjugate vaccine to Kazakhstan for 10 years after localization of contract production of the innovative vaccine in the territory of the country.
Patrick van der Loo, Regional President of Pfizer for Middle East, Russia and Africa, arrived in Kazakhstan to sign the document.
Kazakhstan became the first country in the Eurasian region and Central Asia where Pfizer plans to establish contract production of the innovative vaccine.
In February 2023, a roadmap for the implementation of the project was signed between Pfizer, Kazakhstan’s healthcare and foreign affairs ministries.
The vaccination against pneumococcal infection has been included in the National Immunization Schedule of Kazakhstan since 2010. Prior to the launch of mass immunization, pneumonia was one of the leading causes of death in infants in the country. The introduction of vaccination into the National Immunization Schedule made it possible to reduce the mortality rate among children in this age group by more than 2.5 times.
Photo: Pixabay.
